INTRODUCTION
Cardiovascular disease (CVD) and other noninfectious chronic disease (NCD) has become one of the global concerns, especially in developing countries. 1 CVD is the primary cause of death worldwide. It is estimated that, up to 2030, there will be 23.3 million people dead due to CVD. 2 According to World Health Organization, about 4.23 million people died of Coronary Artery Heart Disease (CHD) every year. 3 The American Heart Association (AHA) study found that the heart attack caused by angina accounted for 18% and it also cost a lot. 4 Angina pectoris (AP) with the symptoms of intense tightness or heavy pressure in the chest, radiating to the neck, jaw, shoulder, back, arm, and epigastric region can be caused by myocardial ischemia. 5 Nowadays, we usually treated the AP by drugs, intervention therapy and so on. The 2011 updated guidelines of the AHA recommended the following drugs for the secondary prevention in patients with coronary atherosclerosis, which were antiplatelet drugs, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blocker (ARB), aldosterone antagonists and B-Blocker.
In addition, risk factors should also be controlled positively such as blood pressure, blood lipids, blood glucose and body weight, as well as combining with cardiac rehabilitation therapy. 6 The Sini decoction is a recipe documented in the On Harm Caused by Cold a medical textbook in Traditional Chinese Medicine (TCM). It was originally used to treat shaoyin diseases in terms of TCM theory. In the 1960s, there were already some literature reporting the treatment of cold limbs with Sini decoctionth. But most of them were case reports mainly discussing their personal pplication and understanding of Pathogenesis. [7] [8] [9] [10] [11] [12] Until 1970s, some articles began to report Sini decoction's effects on myocardial infarction or septic shock. [13] [14] [15] [16] [17] [18] [19] On the early 1980s, people tended to concern about the pharmacological effects of Sini decoction, such as protection of the myocardium, improvement of cardiac function, prevention of ischemia-reperfusion and so on. [20] [21] [22] [23] [24] Up to now, many clinical studies and animal experiments were related to Sini decoction for AP. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Moreover, those literatures indicated that Sini decoction were effective for the patients with AP, especially for yang deficiency syndrome or coagulated cold syndrome. 35, 38 So far, there were lacking such a systematic review about Sini decoction, which is the classic recipe of TCM. Therefore, in order to answer the question whether our classic recipe of TCM is effective and safe as an adjuvant therapy, we conducted this systematic review as the objective evidence for clinical application and studies.
METHODS
This systematic review had already been registered on PROSPERO (http://www.crd.york.ac.uk/prospero/). And the registration number is: CRD42014015036.
Search strategy
We searched six electronic databases: PubMed (January 1966 to August 2014), Excerpt Medica Database (EM-BASE) (January 1966 to August 2014), the Cochrane library (January 1966 to August 2014), Wanfang Database (January 1987 to August 2014), China National Knowledge Infrastructure Database (January 1979 to August 2014), China Science and Technology Journal Database (January 1989 to August 2014). The search terms included Fuzi (Radix Aconiti Lateralis Preparata), Ganjiang (Rhizoma Zingiberis), stir-frying with liquid adjuvant Gancao (Radix Glycyrrhizae), Sini, CHD and angina. In the Chinese database, all the terms were used as the key words ("prepared common monkshood daughter root or dried ginger or glycyrrhiza or Sini decoction" and "CHD or angina"). In the English database, the search terms included "Sini decoction or Sini tang" as a MeSH term, and then "CHD or angina or AP" for a second retrieval. Studies published in both English and Chinese were retrieved. Additionally, citations of relevant systematic reviews were also searched for any potential studies that were missed in the electronic database. 28 
Eligibility criteria
Types of studies: two reviewers independently selected available randomized controlled trials (RCTs), regardless of blinding methods, types of publication and languages.
Types of participants
AP with the symptoms of intense tightness or heavy pressure in the chest, radiating to the neck, jaw, shoulder, back, arm and epigastric region can be caused by myocardial ischemia. 5 Those participants were already diagnosed as AP, according to the nationally or internationally recognized diagnostic criteria. If traditional Chinese syndromes were diagnosed, they also should have the nationally established diagnostic criteria.
Types of interventions
The interventions of test group included Sini decoction only or Sini decoction together with basic western medicine treatment. The preparation form of Sini decoction had no limitation, such as decoction, capsules and so on. Moreover, the control group could choose western medicine treatment, including basic therapy, positive drug and placebo. The duration of the treatment should be more than 2 weeks.
Types of comparisons
The comparisons test group included Sini decoction only or Sini decoction together with basic western medicine treatment. Moreover, the control group could choose western medicine treatment, including basic therapy, positive drug and placebo.
Types of outcomes
The outcomes were as follows: (a) The primary outcome was fatality. (b) The secondary outcomes contained number of angina attacks, duration of angina attacks, dosage of nitroglycerin, angina symptoms changes, improvements of ECG and adverse events. However, the following studies would be excluded. (a) Those were repeated literatures. (b) Those had incomplete data, when we couldn't contact the authors or still couldn't gain the data information even after contacting the authors. (c) TCM preparations were used to control group.
Study selection
Two reviewers independently screened the titles and abstracts of each searched article for potentially eligible studies. And then the full texts were screened for the second time. Disagreement was solved by discussion or the third person.
Data collection and extraction
RCTs evaluating the effects and safety of Sini decoc-tion as an adjuvant therapy for patients with AP were included. Titles and abstracts of searched studies were firstly screened. Then, those possibly eligible were determined eligible by reviewing full text. The inclusion criteria were applied by two authors independently. Any disagreements were resolved by referring to the original article and by discussion. Data were collected independently by two authors in a data extraction form, using Microsoft excel 2003. The following characteristics of the trials were recorded on the extraction form: study (author, year), sample size, gender, age, characteristics of participants, intervention of control group and treat group, duration, baseline, outcome measure, completion rates and indicators of acceptability to users. Disagreements were resolved by reviewing the original paper and by consultation. If there were any important missing data, the authors would be contacted by email or phone whenever possible. The articles which finally still had missing data should be excluded. Three reviewers independently extracted the data from eligible studies, using Microsoft excel 2003 to conduct extraction forms. Reviewers extracted the following data: study (author, year), sample size, gender, age, characteristics of participants, intervention of control group and treat group, duration, baseline, outcome measure, completion rates and indicators of acceptability to users. If there were any important missing data, the authors would be contacted by email or phone whenever possible. The articles which finally still had missing data should be excluded.
Risk of bias
Two reviewers independently assessed the risk of bias for each article, according to the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. The items included the random sequence generation, allocation concealment, blinding of participants and personnel, the blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias (selection bias, non-respondent bias, information bias, language bias and multiple publication bias). In this study, language bias and multiple publication bias may exist. Disagreements were resolved by discussion and adjudicated by a third reviewer when necessary.
Data analysis
Data were analyzed with the RevMan software (version 5.1.0, RevMan software, London, England) from The Cochrane Collaboration. Dichotomous data were presented as risk difference (RD), such as improvements of ECG. While continuous data were presented as mean difference (MD), such as the number of angina attacks, duration of angina attacks, dosage of nitroglycerin. Both dichotomous data and continuous data used 95% confidence intervals (CI). And I-square value measures the heterogeneity. When I 2 ≤ 30%, the heteroge-neity might not be important. When 30% ＜ I 2 ＜ 60% , the heterogeneity might be moderate. When 75% < I 2 < 100%, the heterogeneity might be considerable. 20 If I 2 ≤ 30%, we assessed the data by fixed effect analysis. On the other side, if 30% < I 2 < 75%, we chose the random effect analysis. Besides, publication bias was assessed by the funnel plot, if there were sufficient studies (n > 10). 41 If P < 0.05, the differences of the efficacy between interventions were considered statistically significant. The forest plots present the results of hypothesis testing.
RESULTS

Search flow
According to our initial search, 708 citations were identified in the five databases, in which 223 from the Wanfang Database, 242 from VIP, 139 from CNKI, 0 from PubMed , 0 from the Cochrane library, and 89 were searched from EMbase. Totally 340 citations were primarily selected after excluded the 368 repeated ones. Additionally, 7 relavent systematic reviews totally included 132 RCTs, in which 10 RCTs were related to Sini decoction and 122 RCTs were related to AP. By reading titles and abstracts, we excluded 413 articles due to animal experiments, not Sini decoction and not AP. A total of 37 articles went to the next round of assessment. 5 studies with abstracts were excluded, when there was no response after contacting the authors or still couldn't gain the data information even after contacting the authors. As for the full text screening, 31 articles were excluded because of not meeting the inclusion criteria. In total, 6 randomized clinical trials were eligible and were conducted the Meta-analysis ( Figure  1 ). [35] [36] [37] [38] [39] [40] 
Characteristics of the trials included
The main data of 6 trials were summarized in Table 1 . The age of 453 participants ranged from 44 to 81 years 35, 36, [38] [39] [40] The other RCT compared addition of Sini decoction and isosorbide dinitrate with isosorbide dinitrate. 37 In addition, participants in 4 RCTs had been diagnosed either Yang deficiency syndrome or coagulated cold syndrome. 35, 36, 38, 40 Methodological quality On seven aspects, the methodological quality of 6 included trials was evaluated by the Cochrane risk of bias tool. Only 1 trial compared the baseline, 37 and 1 trial reported no adverse events like Liver or kidney damage. 38 However, none of the 6 trials mentioned following up.
As for the outcomes, 4 trials reported number of angina attacks 35, 36, 38, 39 and duration of angina attacks. 35, 36, 38, 39 3 trials reported dosage of nitroglycerin. 35, 36, 38 6 trials reported angina symptoms changes, [35] [36] [37] [38] [39] [40] and 5 trials reported improvements of ECG. [35] [36] [37] [38] 40 Six trials mentioned the "Randomization" without specific means, in which 1 trial used a randomization list. 37 No one reported blindness, withdraw, and the lost ones. What's more, there was selective report. The methodological quality of eligible trials was generally poor ( Table 2 and Figures 2, 3) .
Meta-analysis
The results of meta-analysis were shown in Figure . [4] [5] [6] [7] According to different outcomes, all the results were summarized in the following sections, respectively
Fatality
All the 6 trials failed to report cardiovascular fatality of angina pectoris.
Number of angina attacks
The number of angina attacks data was reported in 4 trials. 35, 36, 38, 39 The 4 trials have similar interventions, thus they have clinical homogeneity. Due to the obvious statistical heterogeneity (Chi 2 = 8.92, df = 3, P = 0.03, I 2 = 66%), data were analyzed by random effect analysis. The number of angina attacks in Sini decoction group was less than isosorbide dinitrate group, but there were no significant difference between them [P = 0.17, MD = 0.83, 95% CI (-0.35, 2.02)] (Figure 4 ). 
Duration of angina attacks
Duration of angina attacks was reported in 4 trials. 35, 36, 38, 39 The 4 trials have similar interventions, thus they have clinical homogeneity. Due to the moderate statistical heterogeneity, and the data were analyzed by the fixed effect (χ 2 = 3.38, df = 3, P = 0.34, I 2 =11%). In Comparison with isosorbide dinitrate, the meta-analysis showed no significance of angina attacks' duration in Sini decoction [P = 0.36, MD = 0.15, 95% CI: ( -0.17, 0.48)] ( Figure 5 ).
Dosage of nitroglycerin
Dosage of nitroglycerin was reported in 3 trials. 35, 36, 38 The 3 trials have similar interventions, thus they have clinical homogeneity. Due to the moderate statistical heterogeneity, and the data were analyzed by the fixed effect [χ 2 = 1.04, df = 2, P = 0.59, I 2 = 0%]. According to the meta-analysis, the dosage of nitroglycerin in Sini decoction group was less than isosorbide dinitrate group, and there were significant difference between them [P = 0.0008, MD = -0.54, 95%CI (-0.85, 0.22)] ( Figure 6 ).
Improvements of ECG
Improvements of ECG was reported in 6 trials. [35] [36] [37] [38] [39] [40] Different from other interventions, 1 trial compared Sini decoction together with Western Medicine with Western Medicine, whose effective ratio were 60.78% and 58.82%. 37 However, there were no statistical difference between the two groups (P > 0.05). 1 trial used ischemic ST-segment changes to evaluate the ECG improvement, which indicated both Sini decoction and isosorbide dinitrate, both together with nitroglycerin, could restore ischemic ST-segment (P < 0.01). And the difference between two groups was not statistically significant. As for random sequence generation, 1 in 6 trials was at low risk of bias. None reported allocation concealment, blinding outcome assessment, incomplete outcome data and other bias. As for blinding participants, 1 in 6 trials was at high risk of bias. As for selective reporting, all the trials were at high risk of bias.
Random sequence generation (selection bias)
Allocation concealment (selection bias) The 4 trials 35, 36, 38, 40 have similer intervenions, thus they have clinical homogeneity. Due to the moderate tatistical heterogeneity, and the data were analyzed by the fixed effect by using the number of effective cases (χ 2 = 0.05, df = 3, P = 1.00, I 2 = 0%). According to the meta-analysis, there was no significant difference between Sini decoction and isosorbide dinitrate on improving the ECG [P = 0.88, RD = -0.01, 95%CI (-0.12, 0.10)] (Figure 7) .
Adverse events
Only 1 trial mentioned there were no adverse events like liver or kidney damage, 38 whereas the other 5 trials were lack of description of adverse events.
DISCUSSION
The results of this study suggest that Sini decoction may have some effects on reducing the dosage of nitroglycerin. However, there was no statistical difference between the Sini decoction group and isosorbide dinitrate group on reducing the number of angina attack, duration and ECG improvement. In addition, none of the six included literatures reported mortality, only one of them reported no adverse events, and the remaining five did not report adverse events. Based on this systematic review, Sini decoction can reduce the dosage of nitroglycerin, when compared with isosorbide dinitrate group. There were no enough evidence to make conclusion for its safety. Thus, further rigorous and well-reported RCTs which can reflect the only effects of Sini decoction are still warranted. The main limitations are: (a) Search flow: the search strategy of this study is not complete enough. The electronic databases did not include English databases and other language database and gray literature (such as meetings, seminars, etc.). Therefore, such kinds of data missing may lead to publication bias.
(b) The methodological quality: quality of literature retrieved was generally low in this study. Most studies only mentioned "randomization", one of the studies mentioned the random list; none mentioned the concealment of the allocation; none mentioned blinding; none reported withdraws or lost to follow-up, and there is selective reporting. In addition, only one study mentioned the baseline comparable. Selection of subjects: four studies selected internationally recognized World Health Organization diagnostic criteria for AP; two other studies used the diagnostic criteria in the 1980 National Medical Conference "recommendation on CHD naming and diagnostic criteria" and " clinical research guidelines about medicine in cardiovascular system, from cardiovascular system of the Ministry of Health of Pharmacy and Pharmacology Base". No one explicated the types of AP. The three studies indicated the TCM syndrome differentiation, all related to the domestic standard which were diagnosed Yang deficiency or cold coagulation syndromes. They may affect the results of this study. (c) Sample size: sample size of included studies is generally small, ranging from 30 to 152 cases. And only 453 participants were included in this study. The small sample size may impact the results of the meta-analysis. (d) Heterogeneity: statistical heterogeneity can be found on such outcomes as number of angina attacks. The possible reasons are as follows: although all the trials have the inclusion criteria for AP, but those inclusion criteria are different; the component of Sini decoction in test groups are not totally the same. According to different syndromes, the dosage or type of several Traditional Chinese Medicine may be changed a bit, which may increase the statistical heterogeneity; the differences in manufacturer factory or quality standard of isosorbide dinitrate may also lead to heterogeneity. Currently, we still lack rigorous multi-center, randomized controlled trials of TCM. And most literatures about TCM were of low quality. The report should imitate the international standard CONSORT format. In addition, TCM mostly met the problem about identification symptom patterns in terms of TCM theory It is necessary to establish a unified specifications and standard forf TCM symptom patterns to facilitate further trials to evaluate effects of TCM treatments based on symptom patterns. In conclusion, according to this systematic review, Sini decoction can reduce the dosage of nitroglycerin, when compared with isosorbide dinitrate group. Moreover, Sini decoction wasn't better than isosorbide dinitrate on reducing the number of angina attack, duration and ECG improvements. There were no enough evidence to make conclusion for the safety of Sini decoction.due to the low methodological quality of the trials collected and lack of the important outcome indicators and adverse events documented. Although the limited evidence indicated that Sini decoction together with nitroglycerin could reduce the dosage of nitroglycerin, it didn't prove only Sini decoction was more effective than isosorbide dinitrate on the treatment of AP. According to Meta-analysis, Sini decoction wasn't better than isosorbide dinitrate in terms of the number of angina attack, duration and ECG improvements.
